With a one year PEG ratio of 0.27, Gritstone Oncology Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 5.07% of US stocks.
GRTS's went public 1.78 years ago, making it older than just 3.27% of listed US stocks we're tracking.
GRTS's price/sales ratio is 58.25; that's higher than the P/S ratio of 96.29% of US stocks.
Stocks that are quantitatively similar to GRTS, based on their financial statements, market capitalization, and price volatility, are AFMD, SPRO, MORF, UMRX, and CLDX.
Gritstone Oncology, Inc., an immuno-oncology company, engages in developing personalized cancer immunotherapies for various cancer types in the United States. It is developing GRANITE-001, a personalized immunotherapy product for cancer patients; and SLATE-001 for patients with common tumor neoantigens. The company was founded in 2015 and is based in Emeryville, California.
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
Gritstone Oncology, Inc. (GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Jean-Charles Soria, M.D., Ph.D., chief executive officer of Gustave Roussy Cancer Center, has joined the company’s scientific advisory board (SAB). “We are delighted that our co-founder Jean-Charles, a world-class medical oncologist and scientist, has rejoined our SAB following his tenure at AstraZeneca,” said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone Oncology.